Results 281 to 290 of about 2,311,361 (335)

Secondary infection in severe COVID-19 patients: Clinical and Microbial Patterns at a Tertiary Hospital in Vietnam [PDF]

BMC Infect Dis
Anh PH, Vinh C, Lan NPH, Minh HQ, Ngan LTQ, Thao HP, Nguyen MTS, Dung NT, Jeon Y, Park SE, Duy PT.   +10 more
europepmc   +2 more sources

Antidepressants and the risk of hyponatremia: A multi‐institutional cohort study using observational medical outcomes partnership—Common Data Model

British Journal of Clinical Pharmacology, EarlyView.
Aim Hyponatremia is a common yet potentially serious adverse event associated with antidepressants. Identifying the antidepressant class with the least risk of hyponatremia would improve patient safety. Methods Using electronic medical records from 15 hospitals standardized into Observational Medical Outcomes Partnership Common Data Model (2003–2023 ...
Kyungyeon Jung, Ju Hwan Kim, Da Eun Hyeon, Jeongmoon Ji, Min Young Lee, Hayun Choi, Dong Yun Lee, Min Woo Kim, Yoonmin Jang, Seonghoon Hwang, Jaehyeong Cho, Seok Young Song, Sang Youl Rhee, Jae Myung Cha, Won‐Woo Seo, Chang‐Won Jeong, Seung‐Jin Kwag, Woo Jin Kim, Jaeuk Hwang, Min‐ho Kim, Rae Woong Park, Ju‐Young Shin   +21 more
wiley   +1 more source

Clinical outcomes of sotrovimab in seronegative patients with severe COVID-19: A multicenter retrospective study. [PDF]

Medicine (Baltimore)
Lobato-Cano R, Prinet L, Romero-Palacios A, Martín-Peral MP, de la Flor-Fuentes AM, Hidalgo-Tenorio C, García-Ocaña PP, Hidalgo-Castellón A, Murillo-Pineda M, Corrales-Cuevas M, López-Cárdenas S.   +10 more
europepmc   +1 more source

Ocrelizumab‐induced colitis: VigiBase disproportionality analysis, case reports and literature review

British Journal of Clinical Pharmacology, EarlyView.
Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse, Christophe Hommel, Nadine Petitpain, Philippe Kerschen   +3 more
wiley   +1 more source

Ischaemic heart disease is the factor associated with severe COVID-19 in the urban population of Uzbekistan: a single‑center retrospective study. [PDF]

BMC Infect Dis
Ibadullaeva N, Musabaev E, Khikmatullaeva A, Padyukov L.   +3 more
europepmc   +1 more source

Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle‐Aquitaine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The French authorities mandated the use of secure prescriptions for pregabalin on May 2021. This study aimed to evaluate the impact of this measure on pregabalin use and misuse in Nouvelle‐Aquitaine, a southwestern French region with around six million inhabitants.
Maika Munech‐Herran, Véronique Moysan, Bruno Lescarret, Clément Mathieu, Antoine Pariente, Nicolas Rousselot   +5 more
wiley   +1 more source

Recurrent severe COVID-19 with Good's syndrome in a patient after thymoma surgery: A case report. [PDF]

Medicine (Baltimore)
Zhang H, Liu H.
europepmc   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source

Quantifying selection bias due to unobserved patients in pharmacoepidemiologic studies of severe COVID-19 cohorts. [PDF]

BMC Med Res Methodol
Bokern M, Rentsch CT, Quint J, Schultze A, Douglas IJ.   +4 more
europepmc   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source